Longeveron (LGVN) Common Equity (2020 - 2026)
Longeveron (LGVN) recorded quarterly Common Equity of $16.0 million in Q1 2026, up 182.41% quarter-over-quarter from $5.7 million in Q4 2025, and down 6.59% on a YoY basis from $17.2 million in Q1 2025.
Longeveron (LGVN) Common Equity (2020 - 2026) Analysis & Trends
Longeveron's Common Equity history runs 7 years deep, the most recent figure standing at $16.0 million for Q1 2026.
- In Q1 2026, Common Equity fell 6.59% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 6.59% YoY), while the FY2025 annual figure was $5.7 million, down 74.07% from the prior year.
- Common Equity was $16.0 million for Q1 2026 at Longeveron, up from $5.7 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $34.3 million in Q1 2022 to a low of $3.0 million in Q1 2024.
- Historically, Common Equity has averaged $16.3 million across 5 years, with a median of $16.0 million in 2026.
- The sharpest annual moves came in 2024 and 2025: Common Equity plunged 81.36% in 2024, then surged 464.22% in 2025.
- A 5-year view of Common Equity shows it stood at $20.5 million in 2022, then plunged by 67.12% to $6.7 million in 2023, then soared by 224.68% to $21.9 million in 2024, then plunged by 74.07% to $5.7 million in 2025, then soared by 182.41% to $16.0 million in 2026.
- The last three Common Equity figures came in at $16.0 million (Q1 2026), $5.7 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 16.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.03 Mn |
| Dec 31, 2025 | 5.68 Mn |
| Sep 30, 2025 | 9.97 Mn |
| Jun 30, 2025 | 12.66 Mn |
| Mar 31, 2025 | 17.16 Mn |
| Dec 31, 2024 | 21.89 Mn |
| Sep 30, 2024 | 25.63 Mn |
| Jun 30, 2024 | 14.91 Mn |
| Mar 31, 2024 | 3.04 Mn |
| Dec 31, 2023 | 6.74 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | 11.26 Mn |
| Mar 31, 2023 | 16.32 Mn |
| Dec 31, 2022 | 20.50 Mn |
| Sep 30, 2022 | 24.62 Mn |
| Jun 30, 2022 | 29.38 Mn |
| Mar 31, 2022 | 34.31 Mn |
| Dec 31, 2021 | 37.45 Mn |
| Dec 31, 2020 | 1.96 Mn |